Structural and functional diseases of the heart muscle itself, separate from clogged arteries or leaking valves, fall into five clinically recognized categories. The five recognized patterns are dilated, hypertrophic, restrictive, arrhythmogenic, and unclassified forms like left ventricular non-compaction or stress-induced takotsubo. Telling them apart shapes prognosis, family-screening plans, and treatment choices, which makes the diagnostic label the starting point, not the finish line.
This guide walks through each of the five recognized cardiomyopathy patterns, exploring how they differ structurally, what symptoms they tend to share, and how cardiologists separate one from another during diagnosis.
The Shared Foundation Behind Every Cardiomyopathy Diagnosis
Every cardiomyopathy diagnosis begins with a structural or functional problem in the myocardium, the muscular wall that pumps blood. Coronary artery disease and valve disorders live in a different category because the muscle itself stays healthy until late-stage damage sets in.
All forms share one downstream consequence: the heart’s ability to fill with blood or push it out efficiently becomes compromised. Systolic dysfunction describes a weak squeeze, while diastolic dysfunction describes stiff walls that refuse to relax. Some subtypes show one, some show the other, and a few show both.
Cardiology societies group these diseases by the dominant structural change visible on imaging:
- Dilated chambers with thin walls that pump poorly
- Thickened walls that crowd the chamber and obstruct outflow
- Stiff walls with normal thickness but poor relaxation
- Fatty and fibrous replacement of working muscle
- Unclassified patterns that do not fit the four classic molds
That classification system turns a vague phrase like “weak heart” into a working diagnosis with a real prognosis.
Each structural pattern then becomes the lens through which cardiologists read every subsequent test and decision.
The Five Core Structural Patterns Cardiologists Look For
Dilated cardiomyopathy enlarges the left ventricle and weakens its squeeze. It is the most common subtype in adults and a frequent pathway to chronic heart failure, which is why left ventricular ejection fraction (the percentage of blood pushed out with each beat) drops so low in this group.
Hypertrophic cardiomyopathy thickens the ventricular walls, often from inherited sarcomere gene variants that change how muscle fibers assemble. Wall thickening can obstruct blood leaving the heart, and the condition remains a leading cause of sudden cardiac death in young athletes, which is why pre-participation screening flags it so aggressively.
Restrictive cardiomyopathy stiffens the ventricles so they cannot relax and fill properly. Wall thickness may look normal on imaging, yet diastolic function falls apart. It is the rarest of the three classic forms.
Arrhythmogenic right ventricular cardiomyopathy features fibrofatty replacement of working myocardium, most often in the right ventricle. Desmosomal gene mutations drive the process, and electrical instability tends to show up before mechanical failure does.
Unclassified patterns collect the cases that defy easy placement. Left ventricular non-compaction shows deep trabeculations and a spongy-looking inner wall. Takotsubo cardiomyopathy mimics a heart attack after an acute emotional or physical stressor and usually resolves within weeks. Peripartum cardiomyopathy surfaces in the final month of pregnancy or the months after delivery, a reminder that hormonal and volume shifts can stress a previously healthy heart.
| Subtype | Dominant Structural Change | Typical Trigger |
|---|---|---|
| Dilated | Enlarged left ventricle, weak squeeze | Genetics, viruses, alcohol, chemotherapy, idiopathic |
| Hypertrophic | Thickened ventricular walls | Inherited sarcomere gene variants |
| Restrictive | Stiff ventricles, normal thickness | Infiltrative disease (amyloidosis, sarcoidosis, hemochromatosis) |
| Arrhythmogenic | Fibrofatty replacement, often right ventricle | Desmosomal gene mutations |
| Unclassified | Non-compaction, stress ballooning, peripartum | Developmental, acute stress, pregnancy |
Why “Most Common” Matters Less Than “Most Likely for You”
Dilated cardiomyopathy dominates population statistics, but a young athlete with a family history of sudden death sits squarely in the hypertrophic zone, and a person with new leg swelling after years of well-controlled blood pressure may land in a restrictive workup if amyloidosis is the hidden driver. Population frequency gives context. Personal risk gives the diagnosis.
Causes, Inheritance, and What Sets Each Subtype Apart
Dilated cardiomyopathy stems from a long list of insults. Genetic variants in over 60 genes account for a growing portion of idiopathic cases. Viral infections, chronic alcohol exposure, and certain chemotherapy agents (most notably anthracyclines) damage myocytes directly. In roughly a third of patients, no trigger is ever identified.
Hypertrophic cardiomyopathy is autosomal dominant in roughly half of cases, meaning a single copy of the variant from one parent is enough to pass risk along. Penetrance and expression vary widely, though, so two relatives with the same mutation can show very different wall thicknesses and symptom severity. Guidance from the American Heart Association emphasizes family screening as a core part of the diagnostic pathway for this reason.
Restrictive cardiomyopathy usually points away from inherited muscle defects and toward infiltrative diseases. Cardiac amyloidosis, including transthyretin amyloid cardiomyopathy (ATTR-CM), deposits misfolded protein between myocytes. Cardiac sarcoidosis creates inflammatory granulomas. Hemochromatosis overloads the heart with iron. Treatment depends entirely on which infiltrative process drives the stiffness.
Arrhythmogenic right ventricular cardiomyopathy traces largely to desmosomal gene mutations that weaken the mechanical connections between myocytes. Over time, those connections fail and fatty tissue replaces working muscle, especially in what cardiologists call the “triangle of dysplasia” on the right side of the heart.
The Genetics Question Worth Asking Early
Asking about a family history of sudden cardiac death, unexplained heart failure, or pacemaker placement before age 50 helps a cardiologist decide whether genetic testing belongs in the workup. A confirmed mutation changes follow-up for relatives, not just the person in the exam room.
A positive genetic finding reshapes the entire clinical picture, including which symptoms should prompt immediate evaluation.
| Subtype | Heritability | Common Non-Genetic Causes |
|---|---|---|
| Dilated | 20–35% familial | Viral myocarditis, alcohol, chemotherapy, idiopathic |
| Hypertrophic | ~50% autosomal dominant | Sporadic sarcomere variants, mimics like hypertension |
| Restrictive | Often non-hereditary | Amyloidosis, sarcoidosis, hemochromatosis, radiation |
| Arrhythmogenic | ~50% familial | Exercise can accelerate phenotype expression |
Recognizing the Symptoms That Overlap and Differ
Shortness of breath, fatigue, chest discomfort, and palpitations appear across multiple subtypes. That overlap is why imaging, not symptoms alone, drives classification. You can describe the same complaints whether the underlying problem is a weak squeeze, a thick wall, or a stiff chamber.
Syncope and exercise-related collapse raise particular concern in hypertrophic and arrhythmogenic forms. In hypertrophic disease, sudden outflow obstruction during exertion can drop cardiac output abruptly. In arrhythmogenic disease, ventricular tachycardia can break out before any structural change shows on a routine exam.
Leg swelling, abdominal fullness, and rapid weight gain from fluid retention signal the heart failure trajectory more typical of dilated disease. The dilated ventricle loses its forward power, blood backs up behind it, and gravity drops fluid into the ankles and belly.
Takotsubo cardiomyopathy mimics a heart attack with crushing chest pain and ST changes on the ECG, but it follows an acute emotional or physical stressor and typically resolves within weeks. Peripartum cardiomyopathy surfaces with the same heart failure signs but in a specific time window around delivery.
Real-World Scenarios Worth Naming
A 22-year-old college soccer player who collapses during a sprint and is found to have a thickened septum fits the hypertrophic pattern. A 58-year-old with new bilateral ankle swelling, an ejection fraction of 25%, and a history of alcohol use fits the dilated pattern. A 72-year-old with thick-looking walls on echo but preserved ejection fraction and a history of bilateral carpal tunnel surgery fits an infiltrative restrictive pattern, since ATTR amyloidosis often shows up that way.
How Cardiologists Distinguish One Type From Another
An echocardiogram measures chamber size, wall thickness, and ejection fraction to sort structural patterns at the first visit. It is fast, radiation-free, and good enough to flag the dominant abnormality in most cases.
A cardiac MRI refines tissue characterization. Late gadolinium enhancement reveals fibrosis. Fatty infiltration shows up in arrhythmogenic disease. Non-compaction patterns become clearer when MRI exposes the spongy inner layer. When echo findings are ambiguous, MRI often closes the gap.
Electrocardiograms and rhythm monitoring flag dangerous arrhythmias associated with hypertrophic and arrhythmogenic subtypes. A 24-hour Holter or longer patch monitor catches non-sustained ventricular tachycardia, which carries weight in sudden-death risk calculators.
Genetic testing and, less commonly, endomyocardial biopsy confirm inherited or infiltrative causes when imaging leaves ambiguity. Academic centers including the Mayo Clinic now routinely pair imaging with genetic panels for first-degree relatives of a confirmed proband.
Ask for the ejection fraction number in writing and ask which wall measurement was abnormal. Those two values tell you almost everything about which subtype the cardiologist is working from.
| Tool | What It Shows Best | Best Used For |
|---|---|---|
| Echocardiogram | Chamber size, wall thickness, EF | First-line classification |
| Cardiac MRI | Fibrosis, fatty infiltration, non-compaction | Echo leaves doubt |
| ECG / Holter | Arrhythmias, conduction disease | Risk stratification in HCM and ARVC |
| Genetic panel | Pathogenic mutations | Family screening |
| Endomyocardial biopsy | Inflammation, amyloid, iron | Suspected infiltrative or inflammatory disease |
Treatment Paths and the Limits of Each Approach
Dilated cardiomyopathy management leans on guideline-directed heart failure drugs, implanted cardioverter-defibrillators for select patients at high arrhythmia risk, and cardiac resynchronization therapy when the electrical conduction system is impaired. None of these tools cures the underlying muscle problem, but they extend life and reduce hospitalizations when chosen for the right patient.
Hypertrophic care focuses on symptom relief, not on shrinking the heart muscle. Beta-blockers and calcium channel blockers slow the heart and improve filling. Surgical myectomy or alcohol septal ablation removes or thins the obstructing muscle when medications fall short. Activity restrictions follow risk stratification rather than a fixed rule, which is why shared decision-making with a specialist matters.
Restrictive and infiltrative disease treatment targets the underlying cause. Amyloid-stabilizing therapy exists for ATTR-CM. Sarcoidosis responds to immunosuppression. Iron chelation treats cardiac hemochromatosis. No drug on the market directly reverses myocardial stiffness, which is why early identification of the infiltrative driver matters so much.
Arrhythmogenic and takotsubo patterns are managed around rhythm protection and trigger removal. Exercise restriction is often advised in arrhythmogenic disease, since sustained exertion can accelerate fibrofatty replacement. Takotsubo management centers on supportive care during the acute phase and addressing the emotional or physical trigger that set it off.
Those same triggers complicate recovery, which is why the closing synthesis brings prognosis, lifestyle, and follow-up back together.
Common Mistakes Worth Avoiding
- Stopping follow-up after one normal echo. Some subtypes evolve slowly and need serial imaging every 1–3 years.
- Skipping family screening. A confirmed genetic mutation in you changes screening for first-degree relatives.
- Treating takotsubo as a heart attack forever. Once function recovers, the diagnosis is takotsubo, not coronary disease.
- Self-prescribing alcohol abstinence only after diagnosis. Cardiologists often recommend abstinence regardless of subtype, since alcohol is a known contributor.
- Ignoring new rhythm symptoms. Palpitations, presyncope, and documented non-sustained ventricular tachycardia belong in front of a specialist quickly.
For any confirmed inherited subtype, ask the cardiology team about a screening protocol for first-degree relatives, including siblings, children, and parents. Early detection saves lives in families with sarcomere or desmosomal variants.
Putting It Together
Cardiomyopathy is not one disease but a family of muscle disorders, and the specific label shapes everything that follows. Dilated, hypertrophic, restrictive, arrhythmogenic, and unclassified forms each carry their own causes, inheritance patterns, symptom signatures, imaging clues, and clinical paths. A confident diagnosis, supported by echo, cardiac MRI, rhythm monitoring, and genetic testing when indicated, gives you the clearest foundation for the decisions ahead.
FAQ
What are the main types of cardiomyopathy?
The five recognized structural patterns are dilated, hypertrophic, restrictive, arrhythmogenic, and unclassified forms such as left ventricular non-compaction and takotsubo. Each pattern describes a different way the heart muscle fails to fill or pump properly, and the classification guides prognosis and clinical decisions.
Which type of cardiomyopathy is most common?
Dilated cardiomyopathy accounts for roughly 60 to 70 percent of adult cases and ranks among the leading pathways to chronic heart failure. Hypertrophic cardiomyopathy is the most common inherited form and a frequent cause of sudden cardiac death in young athletes.
What is the difference between dilated and hypertrophic cardiomyopathy?
Dilated cardiomyopathy enlarges the left ventricle and weakens its squeeze, lowering ejection fraction. Hypertrophic cardiomyopathy thickens the ventricular walls, often obstructing blood flow and predisposing to arrhythmias, while ejection fraction is usually preserved.
Is cardiomyopathy hereditary?
Some forms are strongly hereditary. Hypertrophic and arrhythmogenic cardiomyopathies are autosomal dominant in roughly half of cases, and dilated cardiomyopathy is familial in 20–35% of patients. Restrictive disease is more often driven by infiltrative conditions than by inherited muscle defects.
What tests diagnose cardiomyopathy?
An echocardiogram is usually the first test, followed by cardiac MRI for tissue detail. ECGs and rhythm monitors detect arrhythmias, genetic panels confirm inherited causes, and endomyocardial biopsy is reserved for suspected infiltrative or inflammatory disease.
Can cardiomyopathy be cured?
Most forms cannot be cured in the sense of fully reversing the muscle problem, but clinical care can slow progression, control symptoms, and lower the risk of sudden death. Takotsubo cardiomyopathy often resolves within weeks, and treating the underlying cause of infiltrative restrictive disease can halt further damage.
